Purpose: This Phase 1, open-label, uncontrolled, ascending-dose study explored the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacology of the TLR8 agonist VTX-2337 in subjects with advanced solid tumors or lymphoma.
TRANSLATIONAL RELEVANCE
Targeted modulation of immune responses is becoming an increasingly important tool in the armamentarium of novel strategies to treat cancer. Toll-like receptors recognize the conserved antigenic structures of infectious agents, and stimulate innate immune responses which can activate anti-tumor immunity. We report herein the first-in-man study of a novel small molecule (VTX-2337) that stimulates Toll-like receptor 8 (TLR8).
The data from this study in patients with advanced cancer demonstrate dose-dependent pharmacology and predictable, transient adverse events associated with systemic immune activation. Pro-inflammatory cytokines and chemokines were induced by VTX-2337, provide a reliable set of biomarkers for TLR8 activation, and identified biologically active doses suitable for further evaluation. Based on these data, clinical development of VTX-2337 is being advanced in combination with various anti-cancer agents in multiple solid tumor indications. VTX-2337 highlights the possibility of modulating innate immune responses as a means to induce productive immunity in cancer patients.
INTRODUCTION
Modulation of the host immune response is becoming an increasingly important option in the treatment of a variety of cancers. It is progressively clear that tumor antigen-specific T cell responses, while important, are only one component of anti-tumor immune responses. Ideally, an integrated, pro-inflammatory immune response-likely mediated through cells such as myeloid-derived dendritic cells (mDC) and monocytes capable of secreting inflammatory mediators such as interleukin (IL)-12, IL-1, and tumor necrosis factor-alpha (TNF)-would link innate and adaptive pathways to regulate the priming and amplification of T cell, natural killer (NK) cell, and other cellular responses that may be relevant to the generation of anti-tumor immunity. To this end, we suggest that appropriate stimulation of the innate immune response can provide an important addition to both conventional anti-cancer therapies and some of the newer immunotherapeutic agents such as checkpoint inhibitors.
Activation of the innate immune system is rapid in nature, and tends to involve acute, inflammatory responses to microbial or endogenous ligands. Initiation of the innate immune response in humans and other higher mammalian species is regulated in part by Toll-like Receptors (TLRs). The effects of activating the innate response include alterations in normal leukocyte circulation through blood and tissues, release of soluble mediators, up-regulation of antigen processing and presentation to helper (CD4) and cytolytic (CD8) T-cells, and increases in NK cell function. In the context of an existing cancer, these effects should act in concert to increase the innate and adaptive immune responses to tumor cells, and TLR agonists may be potential candidates for the treatment of various malignancies in humans (1) (2) (3) (4) (5) .
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Author Manuscript Published OnlineFirst on May 7, 2014; DOI: 10.1158/1078-0432.CCR-14-0392 levels were observed at different times after dosing. Many mediators, including granulocyte colony-stimulating factor (G-CSF), IL-6, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1β, were rapidly induced (peaking at approximately 6 hours after dosing). A few, however-including calcitonin and C-reactive protein-had delayed responses, peaking between 12 and 24 hours after dosing (VentiRx, data on file). The only unexpected observation in toxicology studies in the cynomolgus monkey was ocular inflammation, albeit at dose levels considerably higher than would be expected to be used in human clinical applications. Treatment of human peripheral blood cells in vitro with VTX-2337 resulted in increased production of tumor necrosis factor alpha (TNFα) and interleukin (IL)-12 from monocytes and mDC and increased production of interferon IFNγ from NK cells (6) .
On the basis of these initial studies, it was expected that TLR8 activation in humans via VTX-2337 would bolster the body's natural immune response by providing integrated, pro-inflammatory immunomodulatory activity. The Phase 1 study of VTX-2337 reported herein is the first-in-human study, conducted to define single agent safety and tolerability, including identification of the maximum tolerated dose (MTD) for the agent. In addition, the pharmacokinetics and pharmacodynamics of VTX-2337 were investigated, including assessment of the immune-based biomarkers that had been identified in the studies of cynomolgus monkeys and human cells. Anti-tumor activity was also explored.
SUBJECTS AND METHODS
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Author Manuscript Published OnlineFirst on May 7, 2014; DOI: 10.1158/1078-0432.CCR- or causing fever (previous week), lack of acceptable methods of birth control, and pregnancy. At least 3 evaluable subjects were enrolled in each cohort. For this first-in-man study of this novel immunomodulatory agent, we employed a staggered enrollment approach, whereby the first subject in each dose cohort received 2 doses of VTX-2337 prior to enrollment of the remaining 2 subjects for that cohort. Cycle 1 safety data were reviewed for all 3 subjects before the next cohort was enrolled. If 1 of the first 3 subjects in a Research.
Treatment and Dose Escalation
Author Manuscript Published OnlineFirst on May 7, 2014; DOI: 10.1158/1078-0432.CCR-14-0392 dosing cohort experienced a dose-limiting toxicity (DLT), the cohort was expanded to 6 subjects. If 2 or more DLTs were observed, dose escalation was to be halted. The MTD was defined as the dose one level below that at which 2 or more subjects experienced a DLT. DLTs were defined as adverse events that occurred during Cycle 1, were considered by the Investigator to be related to treatment with VTX-2337, and met one of Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. point following dosing; mean fold-increases from baseline values were then calculated for each cohort. If baseline levels were below the level of quantification for the analyte, the lowest quantifiable level for the analyte was used to calculate the fold-increase. For assessment of antitumor responses (complete response [CR], partial response [PR], stable disease [SD], or progressive disease [PD]), measurable lesions at study screening were defined as those that could be accurately measured in a least one dimension with a longest diameter ≥ 20 mm using conventional techniques or ≥ 10 mm with spiral CT scan (18) .
RESULTS
Of the 35 subjects screened for this study, 33 were enrolled and treated with VTX-2337.
Subjects were enrolled into 8 dosing cohorts, ranging from 0.1 to 3.9 mg/m 2 , with 3 to 8 subjects enrolled into each cohort (Table 1) . A total of 16 subjects (48.5%) completed the planned 2 cycles of treatment. Reasons for not completing 2 cycles included: disease progression (n=9, 27.3%); adverse event (n=4, 12.1%); withdrawal of consent (n=3, 9.1%); and death (n=1, 3.0%). Most subjects received 1 cycle (n=12, 36.4%) or 2 cycles (n=13, 39.4%) of VTX-2337 treatment, with 6 (24.2%) subjects entering the extended dosing period and receiving a total of 3 to 8 cycles of treatment.
Demographics
Median age was 65 years (range: 40 to 85); the majority of subjects were male (n=19/33; 57.6%) and all were Caucasian ( Table 2 ). The most prevalent tumor types were colorectal Eight subjects, including 2 replacement subjects, were enrolled in Cohort 8 (3.9 mg/m 2 ).
One of the six evaluable subjects experienced a DLT after administration of the second dose of VTX-2337: Grade 3 hypotension requiring hospitalization. The subject also experienced the non-serious but clinically significant event of Grade 2 cytokine release syndrome. The hypotension resolved the day following dosing, and the subject was discontinued from the study due to this DLT. Although the protocol specified that 2 subjects in a dose cohort experience a DLT in order to establish the MTD, the Investigators and Sponsor considered the study aims to have been met after observing a single DLT. Clear biological activity of VTX-2337 had been established across multiple dose levels (described below), and a range of doses suitable for combination studies had been identified. Thus the highest dose administered was 3.9 mg/m 2 , and resulted in one DLT observed in a single subject.
Safety
The most common adverse events overall were injection site reactions (n=28/33; 84.4%), chills (n=19; 57.6%), pyrexia (n=15; 45.5%), fatigue (n=13; 39.4%), nausea (n=11, 33.3%), influenza-like illness (n=8; 24.2%), decreased appetite (n=8; 24.2%), and vomiting (n=7; 21.2%; Table 3 ). The majority of adverse events were Grade 1 or 2 in severity and were resolved with no additional treatment or with supportive care. Adverse events of Grade 3 severity that occurred in ≥ 2 subjects were anemia, abdominal pain, urinary tract infection, hyponatremia, and cancer pain (n=2; 6.1% each). One subject experienced a Grade 4 event (hepatic encephalopathy), unrelated to VTX-2337. Two (6.1%) subjects died during the study; the deaths were due to progressive metastatic malignant melanoma and hepatic failure secondary to progressive pancreatic carcinoma, respectively. Two (6.1%) additional subjects died within 30 days of receiving VTX-2337; deaths were a result of gastrointestinal hemorrhage in a subject who had received 2 cycles of VTX-2337 before going off study due to disease progression, and metastatic pancreatic carcinoma in a subject who had received 1 cycle of VTX-2337 before going off study prematurely due to rapid disease progression. All 4 deaths were considered by the Investigators to be unrelated to treatment. Four (12.1%) subjects experienced an adverse event that led to treatment discontinuation during Cycles 1 and 2:
hyperbilirubinemia, Escherichia sepsis, hepatic failure, and hypotension. Only hypotension was characterized as treatment-related and it was considered a DLT, as
Author Manuscript Published OnlineFirst on May 7, 2014; DOI: 10.1158/1078-0432.CCR-14-0392 previously described. The most commonly occurring adverse events that were considered by the Investigators as related to treatment included injection site reactions (n=28/33; 84.4%), chills (n=19; 57.6%), pyrexia (n=14; 42.4%), and influenza-like illness (n=8; 24.2%). In general, these events appeared on the day of injection and resolved within 48 hours. The flu-like symptoms, pyrexia, and fatigue were expected and consistent with the pharmacology of VTX-2337. With the exception of a few reports of fatigue that were ongoing at the end of the study, these events resolved without additional treatment or with supportive care. While ocular toxicity was seen in cynomolgus monkeys dosed at high levels of VTX-2337 in non-clinical studies, no VTX-2337 related ophthalmologic toxicity was seen in subjects in this study at any dose level tested.
Pharmacokinetics and Pharmacodynamics
With subcutaneous administration, VTX-2337 was rapidly absorbed into systemic circulation; mean time to maximum concentration (T max ) was approximately 0.5 hours after dosing (Table 4 ). VTX-2337 was also cleared rapidly from circulation; the and disappearance of the chest wall lesion despite the fact that no anti-cancer therapy was given after the subject discontinued VTX-2337. Palliative radiation was directed at the chest wall lesion. Two months following palliative radiation to the lung nodule, all 3 lesions (including the abdominal and skin lesions that were not contiguous with the chest wall lesion and were outside of the radiation field) were undetectable and remain so more than 3.5 years after VTX-2337 treatment (Figure 2 ). Additionally, no instances of VTX-2337 related neurotoxicity, hematotoxicity, or cardiotoxicity were observed.
DISCUSSION

Herein we report the first-in-man
In both humans and cynomolgus monkeys, treatment with VTX-2337 induced dosedependent increases in plasma levels of specific cytokines, chemokines, and other biomarkers of immune activation. This similarity in responses to VTX-2337 is consistent with the observation that the TLR8 receptor is highly conserved between humans and monkeys: TLR8 receptors from humans and Rhesus macaque share 96% amino acid identity and 98% amino acid similarity (16) . The identification of these biomarkers of VTX-2337 activity and characterization of the dose response in cynomolgus monkeys allowed an appropriate starting dose to be selected in this initial clinical study in humans.
We have extensively characterized the in vitro response of human peripheral blood mononuclear cells (PBMC), monocytes, mDC, and NK cells to VTX-2337 in vitro (6) . It should be noted that many of the prominent cytokines induced in vitro via TLR8 activation (notably, IL-12, IL-1 IFNγ) are not detected in the plasma of subjects dosed with VTX-2337. This was not unexpected due to the rapid elimination of many cytokines and chemokines from the systemic circulation, and the assumption that many important cytokines are produced and consumed locally within the immune microenvironments Research.
Author Manuscript Published OnlineFirst on May 7, 2014; DOI: 10.1158/1078-0432.CCR-14-0392 throughout the body. However, in this study, significant levels of specific mediators could be readily measured in a dose-dependent manner after dosing with VTX-2337 ( Figure 1) , and mirror the kinetics and magnitude of the responses seen in cynomolgus monkeys (data not shown). This panel of biomarkers (e.g. G-CSF, MCP-1, MIP-1) demonstrate activation of TLR8 by VTX-2337 after subcutaneous dosing, and provide an important set of markers for subsequent studies in which VTX-2337 will be combined with agents that may modulate the effects of TLR8 activation. It highlights the important distinction between biomarkers identified from in vitro studies to those identified from clinical samples, particularly for agents that modulate immune responses.
To our knowledge, this is the first clinical evaluation of a selective TLR8 agonist in humans. R848 (resiquimod, 3M Pharmaceuticals) is a TLR7/TLR8 agonist that has been studied in man. While it is an activator of TLR8 in vitro, the predominant pharmacology of R848 is consistent with the potent TLR7 agonist activity of this compound. Emerging data including our own underscore the clear differences between activators of TLR8, and TLR7 or TLR9 in human immune responses (21, 22) . TLR8 is expressed on myeloidderived DCs, monocytes, and NK cells in humans (6, 11) , compared to the expression of TLR7 and TLR9 on plasmacytoid-derived DCs (6, 12, 13) . We anticipate these marked differences will lead to a considerably different therapeutic profile of VTX-2337 compared to other TLR agonists previously tested.
Before this study was conducted, it was not known whether a robust immune response to a TLR8 agonist could be expected in cancer patients who had been exposed to repeated It was intriguing to see evidence of potentially delayed treatment response in a patient with metastatic melanoma (Figure 2 ). Several features of this subject are interesting.
First, the initial radiographic assessment indicated progression at the 8 week time point, followed by complete resolution over the ensuing 6 months. Second, the only additional anti-cancer treatment after VTX-2337 was palliative radiation to a lesion that was not contiguous with the other measureable lesions that completely resolved (and remain clear more than 3.5 years later). Delayed responses and a potential abscopal effect of radiation have been reported with other cancer immunotherapies, most clearly with ipilimumab (23) .
The clinical development focus of VTX-2337 will be in combinations with other anticancer therapies. We have demonstrated synergistic activity of VTX-2337 with anthracycline chemotherapy and with various monoclonal antibodies in preclinical studies (6, 22) . The data from the current study provide a clinical rationale for doses of Research.
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